{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:44:59Z","timestamp":1773294299809,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,6,6]],"date-time":"2007-06-06T00:00:00Z","timestamp":1181088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To study the use of antidepressants in children and adolescents in Dutch general practice in 2001 and 2005 and to determine off\u2010label prescribing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were obtained from the Netherlands Information Network of General Practice (LINH) that comprised 97 practices in 2001 and 73 practices in 2005. General practitioners (GPs) recorded prescriptions with their indication in the medical records of the patients during one calendar year. We selected boys and girls aged 0\u201317 years (<jats:italic>n<\/jats:italic>\u2009=\u200983\u2009442 in 2001; <jats:italic>n<\/jats:italic>\u2009=\u200962\u2009969 in 2005) and identified those who got prescribed antidepressants (N06A). Prevalence of use, indications and percentage of off\u2010label prescriptions were compared between 2001 and 2005.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of selective serotonin reuptake inhibitor (SSRI) use decreased from 1.2 to 1.1 per 1000 children and adolescents between 2001 and 2005. The use of tricyclic antidepressants (TCAs) and other antidepressants also decreased (0.8 to 0.7 and 0.3 to 0.2, respectively). TCAs were often prescribed for nocturnal enuresis, but in patients aged 12\u201317 years hyperactivity was the leading indication in both years. GPs continued to prescribe SSRIs for depression (about half of the prescriptions) after the safety warnings, while venlafaxine prescribed for depression decreased in favour of anxiety. Off\u2010label prescribing of SSRIs increased from 16.7% to 34.4% and that of venlafaxine from 22.2% to 58.3%. All SSRI and venlafaxine prescriptions were unlicensed for age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The decreased use of SSRIs and venlafaxine suggests an impact of the safety warnings. A point of concern is the enlarged off\u2010label prescribing and insight in the underlying reasons and its appropriateness is needed. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1430","type":"journal-article","created":{"date-parts":[[2007,6,6]],"date-time":"2007-06-06T10:54:27Z","timestamp":1181127267000},"page":"1054-1062","source":"Crossref","is-referenced-by-count":46,"title":["Antidepressant use and off\u2010label prescribing in children and adolescents in Dutch general practice (2001\u20132005)"],"prefix":"10.1002","volume":"16","author":[{"given":"Anita C.","family":"Volkers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eibert R.","family":"Heerdink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liset","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.157.1.17"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.4.387"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0765-9"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.050468"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7444.879"},{"key":"e_1_2_1_7_2","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA).Seroxat must not be used for treatment in children. June2003.http:\/\/www.mhra.gov.uk\/home(accessed 28 March 2007)."},{"key":"e_1_2_1_8_2","unstructured":"Dutch Medicines Evaluation Board.Dutch Medicines Evaluation Board advices to be careful when using SSRIs in children with a depressive disorder.[in Dutch] December2003. URL:http:\/\/www.homer.nl\/cbg\u2010meb\/index.html?taal=nl(accessed 28 March 2007)."},{"key":"e_1_2_1_9_2","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA).Safety review of antidepressants used by children completed. URL:http:\/\/www.mhra.gov.uk\/home(accessed 28 March 2007)."},{"key":"e_1_2_1_10_2","unstructured":"US Food and Drug Administration (FDA).Worsening depression and suicidality in patients being treated with antidepressant. URL:http:\/\/www.fda.gov\/cder\/drug\/antidepressants\/AntidepressanstPHA.htm(accessed 28 March 2007)."},{"key":"e_1_2_1_11_2","unstructured":"European Medicine agency (EMEA).CHMP meeting on Paroxetine and other SSRIs. December2004. URL:http:\/\/www.cbg\u2010meb.nl\/nl\/docs\/nieuws\/pb\u2010paroxetine.pdf(accessed 28 March 2007)."},{"key":"e_1_2_1_12_2","unstructured":"Dutch Medicines Evaluation Board.Antidepressants in children.[in Dutch] December2004. URL:http:\/\/www.cbg\u2010meb.nl\/nl\/nieuws\/index.htm(accessed 28 March 2007)."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7530.1451"},{"key":"e_1_2_1_14_2","first-page":"S33","article-title":"Effect of government regulatory changes on SSRI prescriptions in children","volume":"15","author":"Kurian BT","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_1_15_2","volume-title":"Effective prescribing antidepressants in general practice. (in Dutch)","author":"Volkers A","year":"2005"},{"key":"e_1_2_1_16_2","unstructured":"Dutch Medicines Evaluation Board (MEB). URL:http:\/\/www.cbg\u2010meb.nl\/(accessed 28 March 2007)."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.111.2.372"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2005.tb01824.x"},{"key":"e_1_2_1_19_2","unstructured":"VerheijRA te BrakeH AbrahamseHA Hoogen van denH BraspenningJ van AlthuisT.Netherlands Information Network of General Practice. Facts and figures about general practitioner care in the Netherlands. NIVEL\/WOK: Utrecht\/Nijmegen the Netherlands. URL:http:\/\/www.LINH.nl(accessed 28 March 2007)."},{"key":"e_1_2_1_20_2","first-page":"265","volume-title":"Morbidity, performance and quality in primary care. Dutch general practice on stage","author":"Verheij R","year":"2006"},{"key":"e_1_2_1_21_2","volume-title":"ICHPPC\u20102\u2010Defined inclusion criteria for the use of the rubrics of the International Classification of Health Problems in Primary care","author":"WONCA Classification Committee","year":"2003"},{"key":"e_1_2_1_22_2","unstructured":"Dutch Medicines Evaluation Board (MEB).http:\/\/www. cbg\u2010meb.nl\/uk\/prodinfo\/index.htm(accessed 28 March)."},{"key":"e_1_2_1_23_2","unstructured":"Pharmaceutical Compass of the Dutch Health Care Insurance Board.www.fk.cvz.nl(assessed 28 March 2007)."},{"key":"e_1_2_1_24_2","unstructured":"Dutch College of general practitioners (NHG).www.formularium.nl\/nhgevs(assessed 28 March 2007)."},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.2.e25"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1258"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1224"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2006.07.003"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.83.6.498"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0752-1"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7349.1312"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000096360"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1430","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T17:19:19Z","timestamp":1699982359000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,6]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1002\/pds.1430"],"URL":"https:\/\/doi.org\/10.1002\/pds.1430","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,6]]}}}